Blockchain Registration Transaction Record

Nutriband's AVERSA Fentanyl Patch Advances Toward FDA Review

Nutriband's AVERSA Fentanyl patch, developed with Kindeva, aims to revolutionize opioid treatment with abuse-deterrent technology, targeting $80M-$200M in U.S. sales.

The development of an abuse-deterrent opioid patch like AVERSA Fentanyl is a critical advancement in the fight against the opioid crisis. By addressing the dual challenges of preventing abuse while ensuring access for patients in genuine need, this innovation has the potential to significantly reduce the risks associated with opioid use. The technology's broad patent protection and substantial market potential underscore its importance in the pharmaceutical industry and public health.